GLSHQ (Gelesis Holdings) Research & Development: $11.90 Mil (TTM As of Jun. 2023)


What is Gelesis Holdings Research & Development?

Gelesis Holdings GLSHQ -99.00% Research & Development is $11.90 Mil as of Jun. 2023.

Research & Development is the aggregate amount of research and development expenses during the year. Gelesis Holdings's Research & Development for the three months ended in Jun. 2023 was $2.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $11.90 Mil.

Gelesis Holdings  (OTCPK:GLSHQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gelesis Holdings Research & Development Related Terms

Gelesis Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Research & Development Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Research & Development
12.87 18.61

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.52 3.37 2.32 3.64 2.58

Gelesis Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $11.90 Mil mean?
Gelesis Holdings (GLSHQ) has a Research & Development of $11.90 Mil as of Jun. 2023. Research and development expense is the total cost for research and development activities. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Research & Development too high?
Gelesis Holdings' current Research & Development is $11.90 Mil.
How does Gelesis Holdings' Research & Development compare to RBSH and PPCB?
Gelesis Holdings' Research & Development of $11.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Research & Development is $11.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Research & Development of $11.90 Mil. The current Research & Development is $11.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Research & Development is $11.90 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.